Maastricht – October 14, 2026 -- More than half of respondents to the MAPPA patient survey received a primary immunodeficiency (PID) diagnosis after age 18, and 28% reported permanent damage at the time of diagnosis, according to preliminary findings Kedrion Biopharma and AIP APS will present at ESID 2026.